Liposome-Coated Arsenic–Manganese Complex for Magnetic Resonance Imaging-Guided Synergistic Therapy Against Carcinoma
Zhexiu Jin,Xue Yi,Jingjing Yang,Meili Zhou,Peifu Wu,Gen Yan
DOI: https://doi.org/10.2147/IJN.S313962
IF: 7.033
2021-06-02
International Journal of Nanomedicine
Abstract:Zhexiu Jin, 1 Xue Yi, 2 Jingjing Yang, 1 Meili Zhou, 1 Peifu Wu, 1 Gen Yan 3 1 Department of Cardiovascular Medicine, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian Province, 361023, People's Republic of China; 2 Department of Basic Medicine, Xiamen Medical College, Xiamen, Fujian Province, 361023, People's Republic of China; 3 Department of Radiology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian Province, 361023, People's Republic of China Correspondence: Gen Yan Department of Radiology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian Province, 361023, People's Republic of China Tel +86 592 627 6910 Email Purpose: A liposome-coated arsenic–manganese complex, denoted as x was constructed for the targeted delivery of arsenic trioxide (ATO) against carcinoma. Methods: Arsenite, the prodrug of ATO, was encapsulated within a liposome via electrostatic interaction with the manganese ions. The as-prepared material was characterized with dynamic light scattering and transmission electron microscopy. The entrapment efficiency and drug loading of arsenic in the carrier were measured using inductively coupled plasma spectrometry. The in vitro release of arsenic was evaluated by using the dialysis bag method. Furthermore, the Fenton-like activity and in vitro cytodynamics research of x were monitored in this work. And the cellular uptake study was used to investigate the in vitro entry mechanism. Furthermore, the cytotoxicity, cell apoptosis and cell cycle study were performed to evaluate the tumor-killing efficiency. Also, the pharmacokinetic and antitumor studies were investigated in HepG2 tumor-bearing nude mice. Results: The as-prepared x possessed a spherical morphology, uniformly distributed hydrodynamic diameter, and excellent drug-loading efficiency. x displayed robust stability and sustained-release profile under physiological environments. x could degrade with high sensitivity to the pH variation in the tumor microenvironment. As such, this could lead to a burst release profile of Mn 2+ and arsenite to achieve a synergistic therapy of chemodynamic therapy and chemotherapy. When compared to the carrier-free arsenate, in vitro experiments revealed that x exhibited enhanced cellular uptake and tumor-killing efficiency. x also demonstrated significantly enhanced tumor-specific in vivo distribution of arsenic, prolonged systemic circulation lifetime, and increased accumulation at the tumor site. Conclusion: Based on the experimental results, x is an ideal arsenic-based nanodelivery system, whereby it can improve the non-specific distribution of NaAsO 2 in vivo. Thus, this work can expand the research and application of arsenic trioxide against solid tumors. Keywords: arsenic–manganese complex liposome, arsenic trioxide, pH-sensitive, hepatocellular carcinoma Primary carcinoma of the liver (PCL) is a type of cancer in the liver cells or intrahepatic bile duct cells, PCL is ranked as the fourth leading cause of cancer-associated deaths worldwide. Among them, hepatocellular carcinoma (HCC) accounts for the vast majority with a high incidence and mortality rate. 1 , 2 Even though various clinically adopted HCC treatment methods have shown to be significant to ameliorate the disease, the use of chemotherapy is often associated with adverse side effects and limited therapeutic efficacy. 3 Thus, due to the limitation of chemotherapy, it is necessary to explore alternative strategies for the treatment of HCC. Arsenic trioxide (ATO) is an active ingredient in traditional Chinese medicine and it has been approved by the United States Food and Drug Administration (FDA) as a first-line antitumor drug against acute promyelocytic leukemia. 4 Furthermore, ATO has also demonstrated excellent antitumor effects on various solid tumors, eg, liver cancer, glioma, and breast cancer, by inhibiting their proliferation and inducing cell apoptosis. 5–10 Clinically, ATO is administered in the form of the arsenite ion (AsO 2 − ). Even though ATO can exhibit excellent antitumor effects, the narrow therapeutic window, the lack of specificity in the body distribution, liver toxicity, neurotoxicity, and skin and nail pigmentation have significantly hindered the mass adoption of ATO in the clinical setting. Thus, to utilize ATO as high efficacy antitumor drug, i -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology